ASP-based Reimbursement For Radiopharmaceuticals Gets PhRMA Support
The Pharmaceutical Research and Manufacturers of America expressed support for using an average sales price-based approach to reimbursing radiopharmaceuticals under Medicare in response to CMS' statement of its willingness to consider switching from reimbursement based on individual hospitals' claims
You may also be interested in...
Change to average sales price based payment for Cell Therapeutics’ radioimmunotherapy could help boost use in community oncology centers.
CMS is willing to consider switching Medicare Part B payment for radiopharmaceuticals to the average sales price formula, the agency says in proposed rules to update Medicare's hospital outpatient prospective payment system for 2009
Food safety programs would get the largest increase in the White House’s proposed fiscal 2015 FDA budget, and increases in user fee programs are proposed as key drivers for the boost. The agency’s overall budget would grow $335 million to $4.7 billion in the proposal.